Antimeningococcal and antipneumococcal vaccination determinants: A European systematic literature review

Epidemiologia e Prevenzione

Volumn 39, Issue 4, 2015, Pages 59-64

  Malerba, Valentina ^a   Costantino, Claudio ^a   Napoli, Giuseppe ^a   Marchese, Valentina ^a   Casuccio, Alessandra ^a   Tabacchi, Garden ^a   Vitale, Francesco ^a   Amicizia, Daniela ^b   Bechini, Angela ^c   Boccalini, Sara ^c   Bonanni, Paolo ^c   Coppola, Rosa Cristina ^d   Fortunato, Francesca ^e   Gasparini, Roberto ^b   Levi, Miriam ^b   Martinelli, Domenico ^e   Panatto, Donatella ^b   Pellizzari, Barbara ^f   Prato, Rosa ^e  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e UNIVERSITY OF FOGGIA   (Italy)

^f CCMR   (Italy)

Author keywords

Meningococcal vaccination; Pneumococcal vaccination; Systematic literature review

Indexed keywords

MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGE; AGED; ATTITUDE TO HEALTH; CHILD; CLINICAL TRIAL; COST; ECONOMICS; EUROPE; FEMALE; HEALTH CARE DELIVERY; HUMAN; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MULTICENTER STUDY; PARENT; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; PSYCHOLOGY; SOCIOECONOMICS; UTILIZATION; VACCINATION; VACCINATION REFUSAL; VERY ELDERLY; VULNERABLE POPULATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; EUROPE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; PARENTS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SOCIOECONOMIC FACTORS; VACCINATION; VACCINATION REFUSAL; VULNERABLE POPULATIONS;

EID: 84968761446     PISSN: 11209763     EISSN: 23851937     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Italian National Vaccination Plan (2012-2014). http://www.salute.gov.it/imgs/C-17-pubblicazioni-1721-allegato.pdf (accessed June 18, 2015).
2. Perkins BA. New opportunities for prevention of meningococcal disease. JAMA 2000;283:2842-43.
3. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2011;60:72-76.
4. Abdelnour A, Silas PE, Lamas MR, et al. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (Men ACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine 2014;32:965-72.
5. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013;381:825-35.
6. Thirlaway K, Lukman H. Meningitis C vaccine uptake by British undergraduates. Commun Dis Public Health 2003;6:157-60.
7. Timmermans DR, Henneman L, Hirasing RA, van der Wal G. Attitudes and risk perception of parents of different ethnic backgrounds regarding meningococcal C vaccination. Vaccine 2005;23(25):3329-35.
8. Theeten H, Hens N, Vandermeulen C, et al. Infant vaccination coverage in 2005 and predictive factors for complete or valid vaccination in Flanders, Belgium: an EPI-survey. Vaccine 2007;25:4940-48.
9. Timmermans DR, Henneman L, Hirasing RA, van der Wal G. Parents' perceived vulnerability and perceived control in preventing Meningococcal C infection: a large-scale interview study about vaccination. BMC Public Health 2008;8:45.
10. Vandermeulen C, Roelants M, Theeten H, et al. Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. Pediatrics 2008;121:e428-34.
11. Theeten H, Vandermeulen C, Roelants M, et al. Coverage of recommended vaccines in children at 7-8 years of age in Flanders, Belgium. Acta Paediatr 2009;98:1307-12.
12. Ganczak M, Dmytrzyk-Daniłów G, et al. Determinants influencing self-paid vaccination coverage, in 0-5 years old Polish children. Vaccine 2013;31:5687-92.
13. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2012;61:816-19.
14. Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012;205:1408-16.
15. Musher DM, Manoff SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010;201:516-24.
16. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007;7:597-606
17. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(RR-9):1-35.
18. Martinelli D, Pedalino B, Cappelli MG, et al. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013. Hum Vaccin Immunother 2014;10:33-39.
19. Rudnik W, Liu Z, Shigayeva A, et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. Vaccine 2013;31:5863-71.
20. Amodio E, Costantino C, Giuffrè M, et al Invasive pneumococcal diseases in children aged 1-59 months in Sicily, Italy: importance of active family paediatrician surveillance and vaccination coverage. EMBJ 2014;9:19-23.
21. Yaqub O, Castle-Clarke S, Sevdalis N, Chataway J. Attitudes to vaccination: a critical review. Soc Sci Med 2014;112:1-11.
22. Sammarco S, Ciofi degli Atti ML, Binkin N, D'Argenio P, Bella A; Gruppo di lavoro "Studio Argento". Vaccine coverage survey of the elderly in 11 Italian regions.[Article in Italian]. Ann Ig 2004;16:701-708.
23. Lode H, Ludwig E, Kassianos G. Pneumococcal infection - low awareness as a potential barrier to vaccination: results of a European study. Adv Ther 2013;30:387-405.
24. Robert E, Dramaix M, Swennen B. Vaccination coverage for infants: cross-sectional studies in two regions of Belgium. Biomed Res Int 2014;2014:ID 838907.
25. Borrow R, Abad R, Trotter C, et al. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 2013;31:4477-86.
26. European Centre for Disease Prevention and Control (ECDC). Vaccine scheduler. Stockholm, ECDC 2013. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx (accessed June 18, 2015).
27. Uman ET, McCauley MM, Shefer A, Chu SY. Maternal characteristics associated with vaccination of young children. Pediatrics 2003; 111:1215-18.